TP53 and colorectal carcinoma: Investigations into oroxin A have revealed its potential to inhibit CRC progression by repressing Sirt3-regulated MDM2 transcription, thereby preventing MDM2-mediated p53 degradation and consequentially diminishing aerobic glycolysis [150].